Business Context and Reporting Period
This Form 8-K was filed by Actinium Pharmaceuticals, Inc. on January 2, 2018. The report discloses the appointment of a new named executive officer and the entry into a material definitive employment agreement.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the appointment of Dale L. Ludwig, Ph.D., as Chief Scientific Officer and a named executive officer, effective January 2, 2018. Dr. Ludwig brings 20 years of experience in oncology antibody drug discovery from Eli Lilly and Company and ImClone Systems, Inc.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for Dr. Ludwig under the new Employment Agreement:
- Base Salary: $325,000 per year.
- Cash Bonus: Target of 30% of base salary, amount determined by the Board.
- Stock Options: Grant of 200,000 common shares with an exercise price equal to the closing price on January 8, 2018.
- Vesting Schedule: 28% vests 12 months after the grant date; the remainder vests at 2% per month thereafter. The option term is 10 years.
- Restrictive Covenants: Includes a 3-year non-competition clause and a 24-month non-solicitation clause post-employment.
The filing does not contain specific guidance, outlook, or risk factors beyond the standard employment terms.
Key Facts for Investor Verification
- Verify the closing stock price on January 8, 2018, to determine the exercise price of the 200,000 options granted.
- Review the Company's Form 10-K for the year ended December 31, 2017, for the full text of the Employment and Indemnification Agreements.
- Assess the impact of the new Chief Scientific Officer's background on the Company's oncology pipeline development.